Ascletis Pharma Inc.
Ascletis Pharma Inc. (ASCLF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
asclf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ascletis Pharma Inc. (ASCLF) measures how much investors pay for each dollar of the company's trailing earnings. ASCLF's current PE ratio of N/A is calculated by dividing its stock price of $1.35 by its TTM earnings per share of -$0.37.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2016 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ascletis Pharma Inc.You ASCLF | $1.4B | N/A | — | -$0.37 |
 BioGaia AB (publ) BIOGY | $1.1B | 30.83x | -33.0% | $3.29 |
 CStone Pharmaceuticals CSPHF | $1.1B | N/A | — | -$0.31 |
 Idorsia Ltd IDRSF | $1.5B | N/A | — | -$0.52 |
 Valneva SE INRLF | $531M | N/A | — | -$0.68 |
 SSY Group Limited LJUIF | $1.2B | 19.53x | -57.6% | $0.16 |
 Life Healthcare Group Holdings Limited LTGHF | $1.0B | 87.77x | +90.6% | $0.15 |
Industry Average 3 peers with valid PE | — | 46.04x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.36 | — | |
2024-12-31 FY2024 | — | $-0.30 | — | |
2023-12-31 FY2023 | — | $-0.13 | — | |
2022-12-31 FY2022 | — | $-0.29 | — | |
2021-12-31 FY2021 | — | $-0.18 | — | |
2020-12-31 FY2020 | — | $-0.20 | — | |
2019-12-31 FY2019 | — | $-0.09 | — | |
2018-12-31 FY2018 | — | $-0.01 | — | |
2017-12-31 FY2017 | — | $-0.05 | — | |
2016-12-31 FY2016 | — | $-0.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ascletis Pharma Inc. (ASCLF) measures how much investors pay for each dollar of the company's trailing earnings. ASCLF's current PE ratio of N/A is calculated by dividing its stock price of $1.35 by its TTM earnings per share of -$0.37.
Frequently asked questions
ASCLF pe ratio · 6 questionsASCLF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.35 and TTM EPS of -$0.37. Data sourced from Financial Modeling Prep via ASCLF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ascletis Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09